Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use

This is the authors' abstract. We don't add key points for this paper.

The background characteristics of biologics users differed in a real-world setting. Our results confirmed findings from RCTs demonstrating that each biologic (omalizumab, mepolizumab, benralizumab, and dupilumab) is associated with decreased exacerbation numbers and corticosteroid-sparing effects, even outside of the controlled settings of RCTs.